Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Lowered to $92 at RBC Capital Following Earnings
May 4, 2021 12:51 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $92.00 (from $93.00) while maintaining a Sector Perform rating following reults.
The analyst commented, "A soft quarter for INCY from combined pandemic/seasonal oncology headwinds, though signs suggest to us... More
Incyte (INCY) Tops Q1 EPS by 4c
May 4, 2021 7:18 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of $0.67, $0.04 better than the analyst estimate of $0.63. Revenue for the quarter came in at $605 million versus the consensus estimate of $656.88 million.
2021... More
